The notices it replaced
- Reissues: PA-18-574 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 2 steps back: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 3 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 4 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 5 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 11 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-20-260.
Who won it before
5,056 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,918,953,764 in first-year total cost, median $244,450.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]267
- Special Emphasis Panel[ZRG1 ETTN-G (12)]236
- Special Emphasis Panel[ZRG1 IMST-H (15)]202
- Special Emphasis Panel[ZRG1 IDM-V (12)]173
- Special Emphasis Panel[ZRG1 IMST-B (12)]158
Most frequent institutions
- PHYSICAL SCIENCES, INC32
- AFFINERGY, LLC28
- EPICYPHER, INC.28
- LYNNTECH, INC.24
- PANORAMA RESEARCH, INC.22
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Leadless Pacemaker Betavoltaic Power Source2R44HL145950-02A1 | CABAUY, PETER | CITY LABS, INC., FL | $2,242,432 | ZRG1 |
| 2021 | Non-opiate topical formulations for treating pain associated with molar extractions2R44DE028208-02A1 | PARR, ALAN | ARCATO LABORATORIES, INC., NC | $1,542,183 | ZRG1 |
| 2021 | Improved Treatment of Distal Radius Fractures Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive2R44AG060881-02 | HESS, BRIAN | REVBIO, INC., MA | $1,368,425 | ZRG1 |
| 2021 | Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery2R44GM130268-02 | BORDBAR, AARASHNEMKOV, TRAVIS | SINOPIA BIOSCIENCES, INC., CA | $1,335,997 | ZRG1 |
| 2021 | A comprehensive quality control testing strategy for engineered cells1R44TR003554-01 | TOMPKINS, CHRISTOPHER JOHN | KROMATID, INC., CO | $1,284,984 | ZRG1 |
| 2021 | A New Device to measure Whole and Tissue Level Bone Strength.1R44AG071034-01 | BURKS, PETERTANG, SIMON YUE-CHEONG | ACTIVE LIFE SCIENTIFIC, INC., CA | $1,213,580 | ZRG1 |
| 2021 | Automated Ultra-Long DNA and RNA Extraction for Long-read Sequencing Applications2R44GM131530-02A1 | BROWN, MARK T | CLAREMONT BIOSOLUTIONS, LLC, CA | $1,164,571 | ZRG1 |
| 2021 | Mechanism to Promote Safe and Efficient Oral Feeding in Preterm Infants2R44HD092210-02A1 | MATHUR, AMIT MOHANOLEKSY, THOMASPINEDA, ROBERTA | PREEMIE-PACER, LLC, MO | $1,062,573 | ZRG1 |
| 2021 | Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles2R44CA232778-02A1 | ASSOULINE, JOE | NANOMEDTRIX, LLC, IA | $1,043,125 | ZRG1 |
| 2021 | Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases2R44CA221553-02A1 | MARGULIES, BRYAN SAMUEL | ZETAGEN THERAPEUTICS, INC., NY | $1,014,441 | ZRG1 |
| 2021 | Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children2R44HL129577-02A1 | CLIFTON, WILL | POLYVASCULAR CORPORATION, TX | $1,007,115 | ZRG1 |
| 2021 | A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis1R44AI157031-01 | FANGER, GARY | RISE THERAPEUTICS, LLC, MD | $1,000,000 | ZRG1 |
| 2021 | Massively Multiplexed dsDNA Invasion Arrays1R44AI157322-01 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2021 | Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia1R44AI157719-01 | CRAIGO, JODI K | CYTOAGENTS, INC., PA | $1,000,000 | ZRG1 |
| 2021 | A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products2R44AI138943-03 | BILLINGSLEY, PETER F. | SANARIA, INC., MD | $1,000,000 | ZRG1 |
| 2021 | Screening for rAAV transduction enhancers2R44AI125043-03 | BOWLIN, TERRY L. | MICROBIOTIX, INC, MA | $999,976 | ZRG1 |
| 2021 | Point-of-Care Rapid RNA test for Zika1R44TR003549-01 | CHO, HYUNDAE | CROSSLIFE TECHNOLOGIES, INC., CA | $999,916 | ZRG1 |
| 2021 | Product optimization to commercialize an oral bacteriophage cocktail that prevents cholera in real-world settings2R44AI142960-03 | CAMILLI, ANDREWYEN, MINMIN | PHAGEPRO, INC., MA | $999,585 | ZRG1 |
| 2021 | Novel therapy for Fragile X syndrome2R44MH115529-03 | MUOTRI, ALYSSON R.TUCCI, FABIO COHEN | EPIGEN BIOSCIENCES, INC., CA | $998,958 | ZRG1 |
| 2021 | A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic1R44AI157081-01 | LAFLEUR, MICHAEL | ARIETIS, MA | $995,100 | ZRG1 |
| 2021 | Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation1R44OD030205-01 | VARADHACHARY, ATULVEGA, STEPHANIE PRISCILLA | FANNIN PARTNERS, LLC, TX | $993,974 | ZRG1 |
| 2021 | Mechanical device for the prevention of VTE in high risk patient populations2R44HL145860-02 | WELSH, JOHN D | OSCIFLEX LLC, PA | $986,710 | ZRG1 |
| 2021 | MycoMEIA - Urine Diagnostic for Aspergillosis1R44AI157572-01 | HANNAN, MICHAELMARR, KIEREN A. | PEARL DIAGNOSTICS, INC., MD | $976,576 | ZRG1 |
| 2021 | An automated, scalable, and rapid AST system for Gonorrhea STIs1R44AI157675-01 | SWIGER, ROY R | ACENXION BIOSYSTEMS, INC., KS | $967,087 | ZRG1 |
| 2021 | A Comprehensive 5K Plus Glycan Microarray2R44GM123820-03 | LI, LEIZHANG, JIAN | Z BIOTECH, LLC, CO | $940,980 | ZRG1 |
| 2021 | Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease2R44DK112435-02A1 | GHOSH, SOUMITRA | AVEXEGEN THERAPEUTICS, INC., CA | $867,924 | ZRG1 |
| 2021 | An Ultrafast Electron Counting Camera for 100 kV Cryo-EM1R44GM140797-01 | BAMMES, BENJAMIN EUGENE | DIRECT ELECTRON, LP, CA | $866,770 | ZRG1 |
| 2021 | PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus1R44AI157650-01 | MACLEOD, IAIN JAMES | ALDATU BIOSCIENCES, INC., MA | $865,501 | ZRG1 |
| 2021 | Clinical Validation of Sinu-Test, A Multiplexed Device for Rapid Diagnosis of Acute Bacterial Sinusitis, to support CLIA Waiver2R44AI150203-02 | HAWKINS, ORIANA E. | ENTVANTAGE DX, TX | $860,876 | ZRG1 |
| 2021 | Platform for genotyping and phenotyping each cell in a high throughput assay2R44GM128472-02 | YELLEN, BENJAMIN BIRON | CELLDOM, INC., CA | $831,964 | ZRG1 |
| 2021 | New Algorithms and Software for Mass Spectrometric Analysis of Intact Proteins and Complexes2R44GM133239-02 | BERN, MARSHALL WAYNE | PROTEIN METRICS, LLC, CA | $799,604 | ZRG1 |
| 2021 | Targeting integrin outside-in signaling for treating sepsis2R44HL142396-02A1 | SKIDGEL, RANDAL A | DUPAGE MEDICAL TECHNOLOGY, INC., IL | $776,915 | ZRG1 |
| 2021 | Development of an automated healthcare system for effective management of patients with chronic diseases.2R44NR018631-02 | YANN, MARGOT | ADVINOW, INC., AZ | $776,150 | ZRG1 |
| 2021 | Novel Small Molecule Anti-Inflammatory Eye Drops for Ocular Graft Versus Host Disease2R44EY029185-02A1 | LIU, AMY | PULSAR LIFE SCIENCES, INC., NC | $749,999 | ZRG1 |
| 2021 | A microED pipeline for the pharmaceutical and biotechnology industry1R44GM140666-01 | BRUHN, JESSICA FOXSCAPIN, GIOVANNA | NANOIMAGING SERVICES, INC., CA | $719,038 | ZRG1 |
| 2021 | A Photo-based Menstrual Blood Loss Metric1R44HD102235-01A1 | BURNETT, DANIEL ROGERSJACOBY, VANESSA | THERANOVA, LLC, CA | $717,254 | ZRG1 |
| 2021 | Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production1R44HL150927-01A1 | NESBITT, NATASHA M. | BLOOD CELL TECHNOLOGIES, LLC, NY | $690,965 | ZRG1 |
| 2021 | Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP1R44AI157593-01 | DONINI, OREOLA | SOLIGENIX, INC., NJ | $636,664 | ZRG1 |
| 2021 | An Agent-Based Modeling Platform for Environmental Biotechnology2R44ES026541-02 | SHIRAZI, FATEMEHSOHEILYPOUR, MOHAMMAD | MICROVI BIOTECH, INC., CA | $630,992 | ZRG1 |
| 2021 | Bioinformatic Tools for Interpretation of Glycan Array Data2R44GM131430-02 | HAAB, BRIAN B.ZHANG, JIAN | Z BIOTECH, LLC, CO | $557,113 | ZRG1 |
| 2021 | Explore Slow-Release Formulation of a Peptide Therapeutic for Migraine1R43NS120440-01 | SOARES, CHRISTOPHER JOSEPH | ACHERX, CA | $500,000 | ZRG1 |
| 2021 | A New and Disruptive Gene Based Therapy for Atrial Fibrillation1R44HL154912-01A1 | MOEN, ROBERT CHARLES | INOMAGEN THERAPEUTICS, INC, IL | $462,689 | ZRG1 |
| 2021 | Improving the performance of an AI-enabled clinical decision support tool for detecting suicidal risk and other mental health concerns1R43MH125461-01 | COHEN, JOSHUA | SPREADING ACTIVATION TECHNOLOGIES, LLC, OH | $459,188 | ZRG1 |
| 2021 | NanoSafe Tested Third Party Verification Process for Characterizing Exposures to Products Containing Engineered Nanomaterials2R44ES030650-02 | HILL, WILLIAM CARY | NANOSAFE, INC., VA | $458,457 | ZRG1 |
| 2021 | Novel Therapeutic Agent for Reversing Vascular Dysfunction in Alzheimer's Disease1R43AG071399-01 | HUSSAIN, SAZID | AIVOCODE, LLP, CA | $433,894 | ZRG1 |
| 2021 | TempO-LINC high throughput, high sensitivity single cell gene expression profiling assay1R43GM140771-01 | SELIGMANN, BRUCE E. | BIOSPYDER TECHNOLOGIES, INC., CA | $402,266 | ZRG1 |
| 2021 | Magnetic Bronchoscope for Improved Pulmonary Access1R43HL156598-01 | BLUME, WALTER | UNANDUP, LLC, MO | $401,401 | ZRG1 |
| 2021 | High-throughput Label-free Biosensor Platform for Rapid Detection of Antigen-specific T Cells with Single Cell Resolution1R43CA254684-01A1 | GHASEMI, FARSHID | WEDDELL TECHNOLOGIES LLC, MA | $400,000 | ZRG1 |
| 2021 | Engineering a potent locally-acting interleukin 12-expressing synthetic self-replicating mRNA to augment responses to anti-PD-1 therapy in neoadjuvant triple negative breast cancer1R43CA250745-01A1 | KITADA, TASUKU | STRAND THERAPEUTICS INC, MA | $399,725 | ZRG1 |
| 2021 | Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy1R43CA254820-01A1 | SHIRKEY-SON, NICOLE J. | LUMINARY THERAPEUTICS, INC., MN | $399,658 | ZRG1 |
| 2021 | VDX-111: A novel targeted therapeutic for triple-negative breast cancer1R44CA250674-01A1 | GARI, HAMID H | VONA ONCOLOGY, LLC, CO | $398,493 | ZRG1 |
| 2021 | Hepatocyte production from ice-free cryopreserved and nanowarmed livers1R43DK126551-01A1 | LEE, CHARLES Y | VITRISTOR LLC, NC | $374,262 | ZRG1 |
| 2021 | A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders1R44NS119147-01A1 | SALEH, ANTHONY D | MIRECULE, INC., MD | $370,531 | ZRG1 |
| 2021 | Tackling the MARCKS-PIP3 Circuit to Attenuate Chronic Pulmonary Fibrosis1R43HL156578-01 | WU, REEN | EFFECTORBIO, INC., CA | $347,749 | ZRG1 |
| 2021 | iPSC-derived cardiac fibroblast extracellular matrix for cardiac cell therapy1R43HL156351-01 | KAMP, TIMOTHY J.SCHMUCK, ERIC GARY | CELLULAR LOGISTICS INC., WI | $320,678 | ZRG1 |
| 2021 | High-throughput chemical screens for GPCR functional selectivity1R43TR003567-01 | FISCHER, CURT R.KOSURI, SRIRAM | OCTANT, INC., CA | $316,638 | ZRG1 |
| 2021 | Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation1R43HL156706-01 | HAYSTEAD, TIMOTHY ASCARNEO, SCOTT | EYDIS BIO, INC., NC | $309,288 | ZRG1 |
| 2021 | SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV1R44AI157661-01 | CONE, RICHARD | MUCOMMUNE, LLC, NC | $306,500 | ZRG1 |
| 2021 | Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks1R43AI157652-01 | CONE, RICHARD | MUCOMMUNE, LLC, NC | $306,500 | ZRG1 |
| 2021 | High-order Cavities for Enabling High-field MAS-DNP-NMR with Low-cost THz Sources1R43GM140650-01 | DOTY, FRANCIS DAVID | DOTY SCIENTIFIC, INC., SC | $300,001 | ZRG1 |
| 2021 | Next-day whole genome sequencing and analysis using nanopore sequencing for real-time outbreak and transmission determination in healthcare facilities1R43AI156979-01 | SATER, MOHAMAD | DAY ZERO DIAGNOSTICS, INC., MA | $300,000 | ZRG1 |
| 2021 | Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus1R43AI156952-01 | LEBER, ANDREW | BIOTHERAPEUTICS, INC., VA | $300,000 | ZRG1 |
| 2021 | Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential1R44AI157181-01 | GRANT, BETHANY FOCH | KYTOPEN CORP, MA | $300,000 | ZRG1 |
| 2021 | A New HBV Drug For Establishing Durable Antiviral Efficacy of HBV Treatment1R43AI155066-01A1 | ZHANG, YONG-YUAN | HBVTECH, MD | $300,000 | ZRG1 |
| 2021 | Discovery of broad-spectrum, cross-neutralizing bispecific antibodies against SARS-CoV-2 using high throughput functional screening1R43AI157382-01 | WU, GEORGE GUIKAI | AMBERSTONE BIOSCIENCES, INC, CA | $300,000 | ZRG1 |
| 2021 | Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray1R43AI157532-01 | HOFFMAN, STEPHEN LEVJAMES, ERIC ROBERT | SANARIA, INC., MD | $300,000 | ZRG1 |
| 2021 | Manganese-based Contrast Agent for Cardiovascular MRI1R43HL156713-01 | HOFFMAN, VERA | REVEAL PHARMA, MA | $300,000 | ZRG1 |
| 2021 | Development and validation of precision blood volume diagnostic and decision support device for acute decompensated heart failure1R43HL156731-01 | FELDSCHUH, JONATHAN | DAXOR CORPORATION, TN | $299,999 | ZRG1 |
| 2021 | Preclinical Development of GV-MVA-VLP Vaccines Against COVID-191R43AI157578-01 | NEWMAN, MARK | GEOVAX, INC., GA | $299,927 | ZRG1 |
| 2021 | Selection of a lead candidate for the development of a novel anti-inflammatory therapeutic1R43AI155239-01A1 | CAULIN, ALEAH FOX | PEEL THERAPEUTICS, INC., UT | $299,675 | ZRG1 |
| 2021 | A Novel LIGHT/TL1A Bispecific Antibody for the Treatment of Fibrotic Diseases1R43AI157119-01 | FANGER, NEIL A | VIRTICI, LLC, WA | $299,015 | ZRG1 |
| 2021 | Development of Coccidioides Cytokine Release Assay1R43AI152654-01A1 | WHEAT, LAWRENCE JOSEPH | MIRAVISTA DIAGNOSTICS, LLC, IN | $298,530 | ZRG1 |
| 2021 | A Novel Device Alternative to Temporary Diverting Ostomies after Rectal Cancer Surgery1R43CA246987-01A1 | FONG, KENTON DODYAN | SAVAGE MEDICAL, CA | $298,509 | ZRG1 |
| 2021 | Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier1R43HL156334-01 | LIGHT, DAVID RICHARD | ILLEXCOR THERAPEUTICS, LLC, VA | $298,412 | ZRG1 |
| 2021 | Targeted therapeutic delivery to diseased lungs using enucleated mesenchymal stem cells1R43HL156665-01 | WANG, HUAWEI | CYTONUS THERAPEUTICS, INC., OH | $297,553 | ZRG1 |
| 2021 | Humanization of ACE2 and Associated Priming Proteases in New Mouse Models for Downstream Disease and Therapy Investigations of COVID-191R43AI157534-01 | WENG, WEI | INGENIOUS TARGETING LABORATORY, INC., NY | $297,204 | ZRG1 |
| 2021 | A Liposomal Enzyme System for Removal of Ethanol from the Blood1R43AA028974-01 | KOKSHAROV, MIKHAIL | SYNLIFE INC, MA | $295,962 | ZRG1 |
| 2021 | Rapid identification and selection of functional antigen-specific monoclonal antibodies by FcGR-enabled screening on CytoSort Arrays in the CellRaft AIR System1R43AI157022-01 | HARTMAN, JESSICA | CELL MICROSYSTEMS, INC., NC | $292,047 | ZRG1 |
| 2021 | Oral autoantigen therapy for the treatment of Multiple Sclerosis1R43AI155401-01A1 | PILLER, KENNETH J | SOYMEDS, INC., NC | $288,580 | ZRG1 |
| 2021 | Low-cost Production of a Vaccine for Lyme Disease in Maize1R43AI152650-01A1 | EGELKROUT, ERINGOMES-SOLECKI, MARIA | APPLIED BIOTECHNOLOGY INSTITUTE, CA | $282,857 | ZRG1 |
| 2021 | Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections1R44AI157716-01 | PAMULA, VAMSEE K. | BAEBIES, INC., NC | $278,148 | ZRG1 |
| 2021 | Inhalation Repurposing of An Approved Drug to Treat Severe Asthma1R44HL156372-01 | SULLIVAN, JOHN | AEON RESPIRE, INC., CA | $276,752 | ZRG1 |
| 2021 | Real-time, High Resolution Ultrasound-based Image Guidance System for Pericardial Access1R43HL156374-01 | LEE, RANDALL J.MA, IVAN | PERCEPTIVE NAVIGATION, LLC, MD | $261,094 | ZRG1 |
| 2021 | A High-Speed, User-Friendly, Handheld OCT System for Patients who are Unable to Cooperate1R43EY032394-01 | DHALLA, AL-HAFEEZ ZAHIRVIEHLAND, CHRISTIAN | THEIA IMAGING LLC, NC | $259,612 | ZRG1 |
| 2021 | Low Cost OCT Angiography with Spectroscopic Contrast1R43HL156668-01 | BROWN, WILLIAM | LUMEDICA, INC., NC | $259,079 | ZRG1 |
| 2021 | Versatile Eye Tracking for Improved High-resolution Retinal Imaging1R43EY032417-01 | MUJAT, MIRCEA | PHYSICAL SCIENCES, INC, MA | $258,433 | ZRG1 |
| 2021 | Personalized tVNS device for research and treatment of PTSD1R43MH125660-01 | EULIANO, NEIL R. | EVREN TECHNOLOGIES, INC., FL | $256,581 | ZRG1 |
| 2021 | DEPOFILMTM - A NOVEL AND EFFICIENT METHOD FOR PRODUCING ORAL SOLUBLE FILM FOR DRUG DELIVERY1R43GM140539-01 | HARIHARAN, MADHU S | NOVA THIN FILM PHARMACEUTICALS LLC, NC | $256,560 | ZRG1 |
| 2021 | Preclinical Development of VERSAMAB-101 for Spinal Cord Injury1R43NS120397-01 | SUN, MIAO | VERSAPEUTICS INC, CA | $256,122 | ZRG1 |
| 2021 | New BioCascade System for Investigating the Airborne Transmission Modes of Respiratory Viruses1R43AI157123-01 | EIGUREN FERNANDEZ, ARANTZAZU | AEROSOL DYNAMICS, INC., CA | $256,005 | ZRG1 |
| 2021 | Micro Breath Biomarker Analyzer1R43ES032752-01 | NGUYEN, CHIEN | ZEBRA ANALYTIX, INC., AR | $256,000 | ZRG1 |
| 2021 | Polymer-Strengthened AcellularBiologically-Derived Grafts for Pelvic Organ Prolapse1R43HD102296-01A1 | PASHOS, NICHOLAS | BIOAESTHETICS CORPORATION, NC | $255,971 | ZRG1 |
| 2021 | Urgent and unmet need for a long-term solution for increasing pediatric heart-failure population: BiVACOR Rotary Total Artificial Heart1R44HL156370-01 | ADACHI, IKITIMMS, DANIEL | BIVACOR, INC., TX | $255,247 | ZRG1 |
| 2021 | Detecting drug-resistant HBV and HCV variants using a DDS probe array1R43AI156961-01 | SHAFER, DAVID A | GENETAG TECHNOLOGY, INC., GA | $253,385 | ZRG1 |
| 2021 | Sample Barcoding for Ultra High-Throughput Flow Cytometry1R43GM140527-01 | KWOK, SHELDON J.J. | LASE INNOVATION INC., MA | $253,256 | ZRG1 |
| 2021 | Silicon Photonic Detection of anti-ABO Antibodies1R43HL156294-01 | DRURY-STEWART, DANIELLE | SIDX, INC., WA | $253,054 | ZRG1 |
| 2021 | Discovery of inhibitors that target HBx for the treatment of chronic HBV infection1R43AI157533-01 | COBURN, GLEN ANDREW | VENATORX PHARMACEUTICALS, INC., PA | $252,813 | ZRG1 |
| 2021 | Reading workstation for clinical contrast echocardiography1R43HL152939-01A1 | DAVIDSON, BRIAN PEREZSKLENAR, JIRI | NARNAR, LLC, OR | $252,399 | ZRG1 |
| 2021 | Advancing native top-down protein analysis with hybrid SID/ECD technology1R43GM140749-01 | SHAW, JARED BRYAN | E-MSION, INC., OR | $252,070 | ZRG1 |
| 2021 | Novel therapy for myocardial ischemia-reperfusion injury1R43HL149492-01A1 | LARRICK, JAMES WYU, BO | LARIX BIOSCIENCE, LLC, CA | $252,000 | ZRG1 |
| 2021 | Better bioassays via designs for robots analyses with improved model selection and similarity bounds that limit potency bias1R43GM140743-01 | LANSKY, DAVID MATTHEW | PRECISION BIOASSAY, INC, VT | $251,991 | ZRG1 |
| 2021 | Development of an application ("app") for training and assessment of home modification installations for aging in place1R43AG067804-01A1 | TENENBAUM, LOUIS | HOMESRENEWED VENTURES LLC, DC | $251,841 | ZRG1 |
| 2021 | Anatomy-augmented visual training on mobile devices for rapid dissemination of best practices during pandemics1R43GM140751-01 | LEVINE, ROBERT J | ARCHIEMD, INC., FL | $251,643 | ZRG1 |
| 2021 | DEVELOPMENT OF BASELINE GENE EXPRESSION-BASED RESPONSE PREDICTOR FOR ANTI-TNFA THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES1R43DK127578-01 | SWEENEY, TIMOTHY E | INFLAMMATIX, INC., CA | $251,371 | ZRG1 |
| 2021 | Rationally designed lipid- and food-based drug formulations to enhance oral bioavailability1R43GM140759-01 | CARRIER, REBECCA LREZHDO, OLJORA | MECHASIM INC., MA | $251,316 | ZRG1 |
| 2021 | Facile Method for Enhanced Pathogen Detection1R43AI157563-01 | TIAN, HARVEY CHEN | INSO BIOSCIENCES INC, NY | $250,894 | ZRG1 |
| 2021 | Development of Self-Detoxifying Filter Media for Active Decontamination1R43AI157785-01 | BATTAGLIA, DAVID MARK | LYNNTECH, INC., TX | $250,768 | ZRG1 |
| 2021 | Validation of the online Toddler Autism and Development Adaptive Screener (TADAS) at 18 months1R44HD104973-01A1 | HOWARD, BARBARA JOSTURNER, RAYMOND | TOTAL CHILD HEALTH, INC., MD | $250,263 | ZRG1 |
| 2021 | Fast-Track: Improving therapeutic protein purification with new, high-productivity multimodal membranes1R44GM140542-01 | ZHOU, JINXIANG | PURILOGICS, LLC, SC | $250,115 | ZRG1 |
| 2021 | Treatment of Onychomycosis Utilizing Targeted, Controlled High-Frequency Energy1R43AI157174-01 | KING, LAURAVAN DER WEIDE, DANIEL | ACCURE MEDICAL, LLC, WI | $250,114 | ZRG1 |
| 2021 | Mutational profiling in human cells as an in vitro alternative to in vivo mutagenicity assessments1R43ES032751-01 | AUMAN, JAMES TODD | INTEGRATED LABORATORY SYSTEMS, LLC, NC | $249,903 | ZRG1 |
| 2021 | Microglia models for Alzheimer's disease drug screening1R43AG071341-01 | ESSEX, ANTHONY WEBEREVANS, JAMES | PHENOVISTA BIOSCIENCES, LLC, CA | $249,900 | ZRG1 |
| 2021 | Crosslinkable Tissue Particles for Regenerating Craniofacial Bone in an Ovine Model1R43DE029738-01A1 | TOWNSEND, JAKOB | LEEFA BIOTECH, LLC, OK | $249,315 | ZRG1 |
| 2021 | Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.1R43EY032018-01A1 | MALLON, ANDREW PETERMOHAN, RAJIV RAVINDRA | CALISTA THERAPEUTICS, INC., RI | $247,998 | ZRG1 |
| 2021 | Demonstration of repeated Positionally Assisted Negative particle Rejection for High-Speed Sorting1R43GM139436-01 | GRAVES, STEVEN W | BENNUBIO INC, NM | $247,435 | ZRG1 |
| 2021 | Continuous liquid-liquid extractors for doubling of productivity and henhancement of batch based drug manufacturing1R43GM140701-01 | ADAMO, ANDREA | ZAIPUT FLOW TECHNOLOGIES LLC, MA | $247,065 | ZRG1 |
| 2021 | Autoantibody depletion for the therapy of autoimmune disease1R43AI157024-01 | KANNANGANAT SIDHARTHAN, SUNIL | ASTERO ERADO INC, TX | $246,229 | ZRG1 |
| 2021 | Pharmacokinetic Assessment of Peptide-Based Therapy HV-3 for the Treatment of Huntington's Disease1R43NS119006-01 | SCHILB, ANDREW LORING | JANUSQ, LLC, OH | $240,938 | ZRG1 |
| 2021 | A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.1R44AI157776-01 | GANDINI, ALBERTO | ACCEL DIAGNOSTICS, LLC, TX | $240,405 | ZRG1 |
| 2021 | Development of an Usher Gene Therapy1R43EY031603-01A1 | STAERZ, UWE DYANG, JUN | GREFFEX, INC., CO | $227,497 | ZRG1 |
| 2021 | Development of SupraGuard ETT, A Next Generation Composite Endotracheal Tube for the Prevention of Ventilator-Associated Pneumonia1R43HL156363-01 | VACHON, DAVID JOHN | IASIS MOLECULAR SCIENCES, INC, WA | $225,135 | ZRG1 |
| 2021 | High Resolution Mapping of Air Pollutants Using Rideshare and Other Vehicles1R43ES031884-01A1 | BIRKS, JOHN W | LUDLUM MEASUREMENTS, INC., CO | $225,000 | ZRG1 |
| 2021 | Filtration Media for In-Home PFAS Removal from Drinking Water1R43ES032735-01 | DIETZ, STEVEN D | TDA RESEARCH, INC., CO | $225,000 | ZRG1 |
| 2021 | A Photochemically 3D Printed High-Resolution Biodegradable Suture Retention Clip1R43GM140802-01 | RUPPERT, DAVID | DEEP BLUE MEDICAL ADVANCES, INC., NC | $225,000 | ZRG1 |
| 2021 | ViraTag: A Scalable Purification Technology for Adeno-Associated Virus Gene Therapy Vectors1R44GM139503-01A1 | LUGINBUHL, KELLI MICHELLE | ISOLERE BIO, INC., NC | $224,890 | ZRG1 |
| 2021 | Clinical Translation of Near Infrared Nerve-Specific Fluorophores for Nerve-sparing Prostatectomy1R44CA247639-01A1 | BARTH, CONNOR WILLIAM | INHERENT TARGETING, LLC, OR | $224,658 | ZRG1 |
| 2021 | Building a Toolbox to Study the SARS-CoV-2 Proteome1R43AI157021-01 | KAY, BRIAN KENNETH | TANGO BIOSCIENCES, INC., IL | $222,329 | ZRG1 |
| 2021 | Portable, Patient-Administered, Sensor-Enhanced Scalp Cooling Cap and Smartphone App to Reduce Provider Burden, Improve Patient Access, and Improve Patient Outcomes for Chemotherapy-induced Alopecia1R43CA254560-01A1 | DILLIGAN, KATE | COOLER HEADS CARE INC, CA | $210,997 | ZRG1 |
| 2021 | SCIENTIFIC FEASIBILITY OF HIGH FLUORIDE-POVIDONE IODINE TOOTHPASTE1R43DE030303-01 | MILGROM, PETER M | ADP SILVER DENTAL ARREST, LLC, OR | $178,410 | ZRG1 |
| 2021 | Fizz Reader: Interactive Accessible Data Visualizations Through an NLG Interface1R43GM140807-01 | SCHEPERS, DOUGLAS ALAN | FIZZ STUDIO LLC, NC | $175,784 | ZRG1 |
| 2021 | Green and Sustainable in situ Remediation of Heavy Metals Contaminated Soils and Aqueous Systems1R43ES031892-01A1 | ADAM, NADIA | BIOMINERAL SYSTEMS, LLC, IN | $168,087 | ZRG1 |
| 2021 | Development of a commercial assay for the rapid and general detection of PFAS in environmental matrices (Phase I)1R43ES030677-01A1 | MAY, ALEXA | WEAVER LABS, LLC, OK | $167,999 | ZRG1 |
| 2021 | Dual-Tracer PET Tumor Imaging1R43CA257522-01 | KADRMAS, DAN J | MULTIFUNCTIONAL IMAGING, INC., UT | $150,000 | ZRG1 |
| 2021 | Hybridization Chain Reaction: Highly Multiplexed Quantitative RNA and Protein Imaging1R44GM140796-01 | CHOI, HARRY MING TAK | MOLECULAR INSTRUMENTS, INC., CA | $150,000 | ZRG1 |
| 2021 | An Affordable and Improved PM Monitor with Enhanced PM2.5 and Simultaneous PM0.30 Measurement Capabilities1R43ES032640-01 | ANDERSEN, JILL | AIRVIZ INC., PA | $149,825 | ZRG1 |
| 2021 | Scoring ligand/protein interactions using a novel high performance implementation of DFT quantum mechanics1R43GM140578-01 | PEARLMAN, DAVID A | QUANTUM SIMULATION TECHNOLOGIES, INC., MA | $147,454 | ZRG1 |
| 2021 | Same day embryo viability sensor for high throughput embryo transfer selection1R43OD030028-01A1 | BEY, YUSHA | RAVATA SOLUTIONS, INC., CA | $144,560 | ZRG1 |
| 2021 | Intelligent in silico antibody library design and optimization for therapeutic use1R43GM140499-01 | CASTELLANA, NATALIE | DIGITAL PROTEOMICS LLC, CA | $24,590 | ZRG1 |
| 2021 | Software for sequencing human antibody proteins from polyclonal immune responses1R44GM140607-01 | PATEL, ANAND | DIGITAL PROTEOMICS LLC, CA | $23,935 | ZRG1 |
| 2020 | Motion-robust brain MRI for infants1R44MH124567-01 | DECKARD, TODD WILLIAMDOSENBACH, NICOFAIR, DAMIEN A | TURING MEDICAL TECHNOLOGIES INC, MO | $1,790,169 | ZRG1 |
| 2020 | Analgesic Drug for Local Delivery by Fluoroscopy1R44NS120840-01 | BEUTLER, ANDREAS S. | INTERVENTIONAL ANALGESIX, INC., NC | $1,586,882 | ZRG1 |
| 2020 | Inhaled IRK inhibitors as a novel therapeutic for IPF1R44HL151067-01 · under PA-18-574 | HAVA, DAVID L | METERA PHARMACEUTICALS, INC., MA | $1,515,600 | ZRG1 |
| 2020 | Development of Novel Intra-aneurysmal Rapid Occlusion Device2R44NS107048-02 | HEBERT, STEPHEN JKALLMES, DAVID F | NEUROGAMI MEDICAL, INC., CA | $1,499,299 | ZRG1 |
| 2020 | Targeting tau for the development of novel Alzheimer's disease therapeutics2R44AG060843-02 | LARSEN, GLENNWOLOZIN, BENJAMIN L | AQUINNAH PHARMACEUTICALS, INC., MA | $1,475,961 | ZRG1 |
| 2020 | Developing Heparan Sulfate Glycan Array2R44GM123792-03 | SU, GUOWEI | GLYCAN THERAPEUTICS CORPORATION, NC | $1,443,680 | ZRG1 |
| 2020 | Disrupting Insulin Delivery with a Novel, Stabilized Insulin that is Ultra-rapid at U100 or U5001R44DK126613-01A1 | MICHAEL, MERVYN DODSON | THERMALIN, INC., OH | $1,423,451 | ZRG1 |
| 2020 | Microparticle Therapy for Cerebral Amyloid Angiopathy2R44AG059478-03 | KIRSCH, WOLFF M. | KARAMEDICA, INC., NC | $1,380,461 | ZRG1 |
| 2020 | A Novel Bioresorbable Bone Adhesive Used to Fixate Cranial Flaps and Reduce Infection Rates1R44NS115386-01A1 | HESS, BRIAN | REVBIO, INC., MA | $1,325,488 | ZRG1 |
| 2020 | Treating severe asthma in the small airways with a highly efficient and penetrating inhaled dry powder1R44HL152780-01A1 | BEVERLIN II, BRYCE | QUENCH MEDICAL, INC., MN | $1,247,479 | ZRG1 |
| 2020 | PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for SmallBusiness Innovation Research Grant Applications (Parent SBIR [R43/R44] ClinicalTrial Not Allowed1R44NS117214-01A1 | LEVINE, TODD | CND LIFE SCIENCES, INC., AZ | $1,214,227 | ZRG1 |
| 2020 | Novel microfluidic platform for versatile, fast, low-cost DNA synthesis and assembly1R44HG011433-01 | HILL, MATTHEW | ELEGEN CORPORATION, CA | $1,210,045 | ZRG1 |
| 2020 | Solving the MRI motion problem with Framewise Integrated Real-Time MRI Monitoring (FIRMM) software1R44MH121276-01A1 | DECKARD, TODD WILLIAMDOSENBACH, NICOFAIR, DAMIEN A | TURING MEDICAL TECHNOLOGIES INC, MO | $1,190,011 | ZRG1 |
| 2020 | Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer2R44CA228920-02A1 | CASTRO-GONZALEZ, CARLOS | LEUKO LABS, INC., MA | $1,182,313 | ZRG1 |
| 2020 | Proprietary drug to treat radiodermatitis1R44AR078669-01 | WANG, XIAO-JINGYOUNG, CHRISTIAN | ALLANDER BIOTECHNOLOGIES, INC., CO | $1,157,986 | ZRG1 |
| 2020 | A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy2R44CA228622-02 | SCHALK, AMANDA M | ENZYME BY DESIGN, INC., IL | $1,156,734 | ZRG1 |
| 2020 | Development of superior polymerases for next-generation mRNA therapeutic & vaccine manufacturing2R44GM131548-02 | ZIELER, HELGE | PRIMROSE BIO, INC., CA | $1,152,047 | ZRG1 |
| 2020 | Rapid highly multi-plexed immuno-profiling of solid tumors by SpectralEdge imaging2R44CA224503-02 | KALDJIAN, ERICREESE, STEVEN | RARECYTE, INC., WA | $1,145,798 | ZRG1 |
| 2020 | Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer1R44CA257588-01 | SANDANAYAKA, VINCENT | NIROGYONE THERAPEUTICS, LLC, MA | $1,145,470 | ZRG1 |
| 2020 | Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization2R44HD087099-02A1 | ACOSTA, WALTERCRAMER, CAROLE L.RADIN, DAVID | BIOSTRATEGIES, LC, AR | $1,144,737 | ZRG1 |
| 2020 | Clinical Development and Evaluation of a Deep Learning Approach to Improve Diagnostic Accuracy2R44DC017422-02 | SHELTON, RYAN L | PHOTONICARE, INC., IL | $1,136,886 | ZRG1 |
| 2020 | Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment1R44TR003162-01 · under PA-18-574 | ABI GERGES, NAJAH | ANABIOS CORPORATION, CA | $1,132,289 | ZRG1 |
| 2020 | CDK8/19 inhibitors for therapy of advanced prostate cancer2R44CA203184-02A1 | CHEN, MENGQIANLILLY, MICHAEL BRONINSON, IGOR BSHIOZAWA, YUSUKE | SENEX BIOTECHNOLOGY, INC., SC | $1,130,935 | ZRG1 |
| 2020 | IMPROVEMENT TO OZONATING WATER FOR POST-HARVEST WASHING THROUGH NANOBUBBLES2R44FD006465-02 | HAY, TODD | EN SOLUCION, INC., DE | $1,120,586 | ZRG1 |
| 2020 | Natural Glycans for Functional Glycomics2R44GM133252-02 | SMITH, DAVID FLETCHER | NATGLYCAN, LLC, GA | $1,090,714 | ZRG1 |
| 2020 | Probe for Quantitative Fluorescence. Phase 22R44NS108845-02 | ROBERTS, DAVID W | INSIGHT SURGICAL TECHNOLOGIES INC., NH | $1,088,424 | ZRG1 |
| 2020 | Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening1R44HG011442-01 | TOMPKINS, CHRISTOPHER JOHN | KROMATID, INC., CO | $1,088,162 | ZRG1 |
| 2020 | Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons2R44NS108869-02 | KATIYAR, KRITIKA | AXONOVA MEDICAL, LLC, PA | $1,083,394 | ZRG1 |
| 2020 | Multiplexed Nucleation Approaches for Enhanced High Throughput Screening of Co-Crystals2R44GM116285-02 | BOND, ANDREW H. | DENOVX, LLC, IL | $1,078,661 | ZRG1 |
| 2020 | A Proton Tomography System for Optimization of Proton Therapy1R44CA243939-01A1 | DEJONGH, DON F | PROTONVDA LLC, IL | $1,076,547 | ZRG1 |
| 2020 | Aerosolized Vitamin A: Impact on Neonatal Lung Maturation, Hyperoxic Lung Injury and Bronchopulmonary Dysplasia2R44HL142353-02A1 | GELFAND, CRAIGREHAN, VIRENDER K | ADVENT THERAPEUTICS, INC., PA | $1,071,824 | ZRG1 |
| 2020 | Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases2R44DK116450-04 | BLITZER, JEREMYSUMMERS, SCOTT A | POTRERO HILL THERAPEUTICS, INC., CA | $1,069,999 | ZRG1 |
| 2020 | Ergonomic fluorescence-guided surgery imaging platform for intraoperative assessment of blood and lymphatic vasculature2R44CA206754-02A1 | USELMANN, ADAM JOHN | ONLUME, LLC, WI | $1,057,099 | ZRG1 |
| 2020 | Paradigm Surgical Phase II-Development and Validation of SafeClose Roller Mesh Augmentation System for Hernia Treatment and Prevention2R44GM123789-02 · under PA-18-574 | FISCHER, JOHN PATRICKPETERS, REX | PARADIGM SURGICAL, LLC, PA | $1,026,094 | ZRG1 |
| 2020 | Gas Chromatography-Molecular Rotational Resonance Spectrometer1R44GM139446-01 | NEILL, JUSTIN LINDSAY | BRIGHTSPEC, INC., VA | $1,011,550 | ZRG1 |
| 2020 | Development of synthetic sphingolipids for prostate cancer therapy1R44CA257568-01 | GIL, DANIEL | SIEGE PHARMACEUTICALS, INC., CA | $1,008,833 | ZRG1 |
| 2020 | Urine Diagnostic Tool for the Detection of High-grade Prostate Cancer1R44CA254692-01 | NIKNAFS, YASHAR SHARIFI | LYNX DX, INC., MI | $1,004,315 | ZRG1 |
| 2020 | Instrument for Holographic Characterization of Protein Aggregates2R44TR001590-04A1 | PHILIPS, LAURA A | SPHERYX, INC., NY | $1,003,165 | ZRG1 |
| 2020 | Therapeutic UV Disinfection System to Prevent Catheter Related Bloodstream Infections (CRBSIs) in Patients with Peripherally Inserted Central Catheters (PICCs)2R44AI134553-02A1 · under PA-18-574 | FOURKAS, MICHAELRASOOLY, JULIA | PURACATH MEDICAL, INC., CA | $1,000,000 | ZRG1 |
| 2020 | MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial1R44AI149807-01 · under PA-18-574 | LAGENAUR, LAUREL A. | OSEL, INC., CA | $1,000,000 | ZRG1 |
| 2020 | Therapy and Prophylaxis for Genital Tract Infection2R44AI104067-04A1 · under PA-18-574 | AUCI, DOMINICKRUSSELL, MICHAEL W | THERAPYX, INC., NY | $1,000,000 | ZRG1 |
| 2020 | A Once-Weekly Oral Tacrolimus-Prednisone Fixed-Dose Combination Therapy for Post-Transplant Maintenance Immunosuppressive Therapy1R44AI149979-01 · under PA-18-574 | ZALE, STEPHEN | LYNDRA THERAPEUTICS, INC., MA | $1,000,000 | ZRG1 |
| 2020 | Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor1R44CA247134-01 · under PA-18-574 | HOLTSBERG, FREDERICK WAYNESINTIM, HERMAN O | KINARX, LLC, MD | $1,000,000 | ZRG1 |
| 2020 | Bloodstream infection detection directly on whole blood2R44AI124871-02A1 · under PA-18-574 | CELEDON, ALFREDO ANDRES | SCANOGEN, INC., MD | $1,000,000 | ZRG1 |
| 2020 | Pre-IND Development of an Arenavirus Antiviral2R44AI112097-05 · under PA-18-574 | HENKEL, GREGORY WILLIAM | ARISAN THERAPEUTICS, INC., CA | $1,000,000 | ZRG1 |
| 2020 | A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups2R44AI124759-02 | MOE, GREGORY ROBERT | OMVAX, INC., CA | $1,000,000 | ZRG1 |
| 2020 | A Culture-Free Platform for Rapid Fungal Pathogen Identification2R44AI109913-04 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2020 | Chikungunya Recombinant Subunit Vaccine2R44AI120388-03A1 | CLEMENTS, DAVID E | HAWAII BIOTECH, INC., HI | $1,000,000 | ZRG1 |
| 2020 | A new class of broad-spectrum antibacterials for treating MDR infections1R44AI152665-01 | TESTA, CHARLES | CURZA INC, UT | $1,000,000 | ZRG1 |
| 2020 | In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine2R44AI085740-06A1 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $1,000,000 | ZRG1 |
| 2020 | Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment2U44CA221567-02A1 | PLACE, ROBERT FSALEH, ANTHONY D | MIRECULE, INC., MD | $1,000,000 | ZRG1 |
| 2020 | Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease1R44AI152628-01A1 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2020 | The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer2R44CA236265-02A1 | ISAACMAN, STEVEN | NANOMETICS, LLC, CA | $1,000,000 | ZRG1 |
| 2020 | Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling2R44AI134502-03 | LEVIN, ANDREW E. | KEPHERA DIAGNOSTICS, LLC, MA | $1,000,000 | ZRG1 |
| 2020 | Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture1R44AI155307-01 | BLATTNER, FREDERICK RLANDRY, CHARLES F | SCARAB GENOMICS, LLC, WI | $1,000,000 | ZRG1 |
| 2020 | A Vaccine for Lymphatic Filariasis, LFGuard™2R44AI140708-02 | CARTER, DARRICK ALBERTKALYANASUNDARAM, RAMASWAMY | PAI LIFE SCIENCES, INC., WA | $1,000,000 | ZRG1 |
| 2020 | Fully-Automated Lesion Characterization in Ultrawide-Field Retinal Images2R44EY028081-02 | BHAT, SANDEEP | EYENUK, INC., CA | $1,000,000 | ZRG1 |
| 2020 | Urine glycated CD59 as novel diabetes biomarker amenable to measure with a point-of-care device1R44DK127725-01 | SAUL, RICHARD | MELLITUS, LLC, MA | $1,000,000 | ZRG1 |
| 2020 | Novel outside-in dialyzer with long filter life and reduced anticoagulation therapies1R44DK125230-01A1 | LABIB, MOHAMED E | NOVAFLUX, INC., NJ | $999,999 | ZRG1 |
| 2020 | Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling1R44GM136083-01 · under PA-18-574 | MAKAROV, SERGEI S | ATTAGENE, INC., NC | $999,998 | ZRG1 |
| 2020 | Cryopreservation of Anopheles Embryos2R44AI088853-06 · under PA-18-574 | BILLINGSLEY, PETER F. | SANARIA, INC., MD | $999,997 | ZRG1 |
Showing the 200 most recent of 5,056 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.